Note 12 - Business Segment Reporting

12 Months Ended

Dec. 31, 2017

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

12.

Business Segment Reporting

The Company manages its operations as

one

segment, drug testing services. As a result, the financial information disclosed herein materially represents all of the financial information related to the Company’s principal operating segment. All Brazil sales are though

one

independent distributor, which is the only customer greater than

10%

of sales. The Company’s revenues by geographic region are as follows:

	Year Ended December 31,
	2017		2016		2015
Consolidated Revenue:
United States	$	26,327	$	25,608	$	25,836
Brazil		13,069		13,083		746
Other Foreign Countries		305		289		393
Total Revenue	$	39,701	$	38,980	$	26,975